Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects

Fundamental and Clinical Pharmacology

Volumn 30, Issue 6, 2016, Pages 625-633

  Aiudi, Anthony ^a   Miller, Benjamin ^a   Krishna, Gopal ^a   Adedoyin, Adedayo ^a   Xiao, Alan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

clinical pharmacology; infectious disease; pharmacokinetics; pharmacokinetics and drug metabolism

Indexed keywords

CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE MOMENT CURVE; ARTICLE; BODY MASS; CAUCASIAN; CHINESE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION RATE CONSTANT; FECES COLOR; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; JAPANESE (PEOPLE); LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; URINE SAMPLING; VOLUME OF DISTRIBUTION AT STEADY-STATE; XEROSTOMIA; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DRUG TOLERANCE; PHYSIOLOGY;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CEPHALOSPORINS; DRUG TOLERANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; PENICILLANIC ACID; PROSPECTIVE STUDIES;

EID: 84994411142     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12227     Document Type: Article

References (11)

1. Sader H.S., Rhomberg P.R., Farrell D.J., Jones R.N. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. (2011) 55 2390–2394.
2. Zhanel G.G., Chung P., Adam H. et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs (2014) 74 31–51.
3. Solomkin J., Hershberger E., Miller B. et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin. Infect. Dis. (2015) 60 1462–1471.
4. Wagenlehner F.M., Umeh O., Steenbergen J., Yuan G., Darouiche R.O. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet (2015) 385 1949–1956.
5. ® (tedizolid phosphate) [prescribing information], Merck & Co., Inc, Kenilworth, NJ, 2016.
6. ® (tedizolid phosphate) [summary of product characteristics], Merck Sharp & Dohme Limited, Hertfordshire, UK, 2015.
7. Chandorkar G., Huntington J.A., Gotfried M.H., Rodvold K.A., Umeh O. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J. Antimicrob. Chemother. (2012) 67 2463–2469.
8. Miller B., Hershberger E., Benziger D., Trinh M., Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob. Agents Chemother. (2012) 56 3086–3091.
9. Yasuda S.U., Zhang L., Huang S.M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin. Pharmacol. Ther. (2008) 84 417–423.
10. Sorgel F., Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. (1993) 31(suppl A) 39–60.
11. Wooley M., Miller B., Krishna G., Hershberger E., Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob. Agents Chemother. (2014) 58 2249–2255.